| Literature DB >> 33457059 |
Elizabeth B McGrath1, Anna Schaal1, Claire Pace1.
Abstract
Research has demonstrated that cancer survivors who receive a survivorship care plan (SCP) have better coordinated follow-up care, higher overall satisfaction, and report significantly fewer posttreatment emotional concerns. The Commission on Cancer, a program of the American College of Surgeons, has developed a standard of care in which 100% of eligible patients are to receive an SCP by the end of 2019. Nurse practitioners at a National Cancer Institute (NCI)-designated academic medical center worked to develop a standardized process to deliver SCPs to all eligible patients. The primary objective of the project was to standardize how SCPs were completed and embed them into the electronic medical record (EMR) using a templated note created for the EMR. Through an interdisciplinary steering committee, survivorship priorities were established and aligned with LIVESTRONG and American Society of Clinical Oncology guidelines. In addition, survivorship care planning was identified as an essential service to be provided by all cancer disease management groups (DMG) at the cancer center. A cancer SCP subcommittee was formed to explore methods to expand the delivery of SCPs and standardize the SCP process. Prior to this project, SCPs were being done by less than 10% of the providers and only for a few diagnoses, and no standardized method of documentation existed prior to this quality improvement initiative. The standardization of the SCP has increased both participation of other DMGs as well as increased the rate of completion to 34%. We believe that continuous reassessment and process improvement will help us reach the Commission on Cancer goal of providing SCPs to all eligible patients.Entities:
Year: 2019 PMID: 33457059 PMCID: PMC7779566 DOI: 10.6004/jadpro.2019.10.5.4
Source DB: PubMed Journal: J Adv Pract Oncol ISSN: 2150-0878
Institute of Medicine Survivorship Care Plan Recommendations
| Upon discharge from cancer treatment, including treatment of recurrences, every patient should be given a record of all care received and important disease characteristics. This should include, at a minimum: |
| • Diagnostic tests performed and results |
| • Tumor characteristics (e.g., site(s), stage and grade, hormonal status, marker information) |
| • Dates of treatment initiation and completion |
| • Surgery, chemotherapy, radiotherapy, transplant, hormonal therapy, gene or other therapies provided, including agents used, treatment regimen, total dosage, identifying number and title of clinical trials (if any), indicators of treatment response, and toxicities experienced during treatment |
| • Psychosocial, nutritional, and other supportive services provided |
| • Full contact information on treating institutions and key individual providers |
| • Identification of a key point of contact and coordinator of continuing care |
Note. Information from Institute of Medicine and National Research Council (2006).
Sample Cancer Flow Sheet
| Date care plan initiated | 7/14/2015 |
| Date of presentation | 8/1/2014 |
| Age at presentation | 62 years old |
| PSA at presentation | 8.31 |
| Presence of symptoms at presentation | Positive |
| Ethnicity | White |
| Result of DRE | Normal |
| Date of TRUS and biopsy | 8/14/2014 |
| Volume in cc | 40 |
| Gleason grade/score a + b = c | – |
| Total cores | 13 |
| Positive cores | 13 |
| Bone scan at presentation | 4 + 5 = 9 |
| Date of bone scan | 9/30/2014 |
| Prostate confined | – |
| ECE | + |
| SV | + |
| Regular nodes | (no data) |
| Distant mets | – |
| Date of MRI | 9/30/2014 |
| Urinary continence at presentation | N |
| Primary therapy | EBRT |
| EBRT date began | 12/29/2014 |
| EBRT total dose (Gy) | 79.2 |
| Treatment fractions | 44 |
| Elapsed date | 3/4/2015 |
| Concurrent ADT | + |
| Histologic type | Adenocarcinoma |
| Post primary therapy: nadir date | 6/4/2015 |
| Post primary therapy: nadir PSA | < 0.03 |
| Adjuvant therapy | LHRH agonist |
| ADT duration in months | 28 |
Note. PSA = prostate-specific antigen; DRE = digital rectal exam; TRUS = transrectal ultrasound; ECE = extracapsular extension; SV = seminal vesicles; EBRT = external beam radiotherapy; ADT = androgen deprivation therapy; LHRH = luteinizing hormone-releasing hormone.
Institute of Medicine–Recommended Standards of Care
| Upon discharge from cancer treatment, every patient and their primary health care provider should receive a written follow-up care plan incorporating available evidence-based standards of care. This should include, at a minimum: |
| • The likely course of recovery from treatment toxicities, as well as need for ongoing health maintenance/adjuvant therapy |
| • A description of recommended cancer screening and other periodic testing and examinations, and the schedule on which they should be performed (and who should provide them) |
| • Information on possible late and long-term effects of treatment and symptoms of such effects; Information on possible signs of recurrence and second tumors |
| • Information on the possible effects of cancer on marital/partner relationship, sexual functioning, work, and parenting, and the potential future need for psychosocial support |
| • Information on the potential insurance, employment, and financial consequences of cancer and, as necessary, referral to counseling, legal aid, and financial assistance |
| • Specific recommendations for healthy behaviors (e.g., diet, exercise, healthy weight, sunscreen use, virus protection, smoking cessation, osteoporosis prevention) |
| • When appropriate, recommendations that first-degree relatives be informed about their increased risk and the need for cancer screening (e.g., breast cancer, colorectal cancer, prostate cancer) |
| • As appropriate, information on genetic counseling and testing to identify high-risk individuals who could benefit from more comprehensive cancer surveillance, chemoprevention, or risk-reducing surgery |
| • As appropriate, information on known effective chemoprevention strategies for secondary prevention (e.g., tamoxifen in women at high risk for breast cancer; aspirin for colorectal cancer prevention) |
| • Referrals to specific follow-up care providers, support groups, and/or the patient’s primary care provider |
| • A listing of cancer-related resources and information (internet-based sources and telephone listings for major cancer support organizations) |
Note. Information from Institute of Medicine and National Research Council (2006).